학술논문

The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells
Document Type
article
Source
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Aging
Urologic Diseases
Prostate Cancer
Cancer
Biotechnology
2.1 Biological and endogenous factors
5.1 Pharmaceuticals
Adult
Aged
Animals
Apoptosis
Cell Line
Tumor
Cyclin-Dependent Kinase Inhibitor p16
E2F Transcription Factors
Gene Expression Regulation
Neoplastic
Humans
Kallikreins
Male
Mice
Nude
Middle Aged
Prostate-Specific Antigen
Prostatic Neoplasms
Receptors
Androgen
Serine Endopeptidases
Signal Transduction
Tumor Suppressor Protein p14ARF
p14ARF
Prostate cancer
Androgen receptor
E2F
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
Prostate cancer (PCa) is characterized by a unique dependence on optimal androgen receptor (AR) activity where physiological androgen concentrations induce proliferation but castrate and supraphysiological levels suppress growth. This feature has been exploited in bipolar androgen therapy (BAT) for castrate resistant malignancies. Here, we investigated the role of the tumor suppressor protein p14ARF in maintaining optimal AR activity and the function of the AR itself in regulating p14ARF levels. We used a tumor tissue array of differing stages and grades to define the relationships between these components and identified a strong positive correlation between p14ARF and AR expression. Mechanistic studies utilizing CWR22 xenograft and cell culture models revealed that a decrease in AR reduced p14ARF expression and deregulated E2F factors, which are linked to p14ARF and AR regulation. Chromatin immunoprecipitation studies identified AR binding sites upstream of p14ARF. p14ARF depletion enhanced AR-dependent PSA and TMPRSS2 transcription, hence p14ARF constrains AR activity. However, p14ARF depletion ultimately results in apoptosis. In PCa cells, AR co-ops p14ARF as part of a feedback mechanism to ensure optimal AR activity for maximal prostate cancer cell survival and proliferation.